托伐普坦对老年慢性心力衰竭患者的疗效及对心容量负荷、血清炎症因子的影响
Clinical effectiveness of torvalptan for chronic heart failure in elderly patients and its effect on cardiac capacity load and serum inflammatory factors

杜香玲.托伐普坦对老年慢性心力衰竭患者的疗效及对心容量负荷、血清炎症因子的影响[J].内科急危重症杂志,2019,25(6):482-485

扫码阅读全文

DOI：10.11768/nkjwzzzz20190612

英文关键词:

基金项目:山东中医药科学技术局项目资助（No:Z2011-1-3-19-2）

作者	单位	E-mail
杜香玲	菏泽市鄄城县第二人民医院	1019667234@qq.com

摘要点击次数: 1809

全文下载次数: 3035

中文摘要:

目的：观察托伐普坦治疗老年慢性心力衰竭(CHF)患者的临床疗效及对心容量负荷、血清炎症因子的影响。方法：将130例老年CHF患者分为对照组与观察组，对照组给予常规治疗，观察组在对照组的基础上给予托伐普坦治疗。观察2组患者治疗前及治疗3个月后心容量负荷指标、血清炎性因子表达水平、心功能指标及血清钠水平的变化情况,并评估其临床疗效。结果：2组临床疗效比较，差异有统计学意义（P＜0.05）；治疗后，2组患者心容量负荷指标、血清炎症因子与心功能指标均较治疗前改善(均P＜0.05)，且观察组各项指标均优于对照组(均P＜0.05)；治疗后，观察组患者血清钠水平较治疗前升高（P＜0.05），对照组较治疗前降低（P＜0.05），观察组患者血清钠水平高于对照组（P＜0.05）。结论：托伐普坦可提高老年CHF患者的临床疗效，降低患者心容量负荷，预防低钠血症，抑制血清炎症因子过高表达。

英文摘要:

Objective: To observe the clinical effectiveness of toparptan for elderly patients with chronic heart failure (CHF) and its effect on cardiac capacity load and serum inflammatory factors. Methods: 130 elderly patients with CHF were divided into the control group and the observation group. The control group was given routine treatment, and the observation group was given topalptan treatment on the basis of the control group. Before and 3 months after treatment, cardiac capacity load index, serum levels of inflammatory factors, cardiac function indexes and the change of serum sodium levels were observed in two groups, and clinical effectiveness was evaluated. Results: The clinical efficacy in the observation group was better than that in the control group (P<0.05). After treatment, the indexes of cardiac capacity load, serum inflammatory factors and cardiac function were significantly improved in both groups as compared with those before treatment (P<0.05). All the indicators in the observation group were better than those in the control group (P<0.05). After treatment, serum sodium level in the observation group was significantly higher than before treatment (P<0.05), that in the control group was significantly lower than before treatment (P<0.05), and that in the observation group was significantly higher than that in the control group (P<0.05). Conclusion: Toparptan can improve the clinical effectiveness of elderly patients with CHF, reduce the load of cardiac capacity, prevent hyponatremia, and inhibit the excessive expression of serum inflammatory factors.